17430CON(AP) PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Baciu et al.)	Group Art Unit: Not yet assigned
Serial No.: Not yet assigned)	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail
Filed: Herewith)	(Label No. EV193716907US in an envelope addressed to: Box Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:
For: METHODS OF SCREENING AND USING INHIBITORS OF ANGIOGENESIS)))	Date of Deposit: 10/29/2003 Person making Deposit: BOND 15 FER GWON Signature: Date of Signature: 10/29 1003
Examiner: Not yet assigned)	, ,

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentablility of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

No fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Carlos A. Eisher Reg. No. 36,510 ALLERGAN, INC.

T2-7H

2525 Dupont Drive Irvine, CA 92612

Tel: 714-246-4920 Fax: 714-246-4249 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

Sheet	_1_	of	1
-------	-----	----	---

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET:	SERIAL NO.:
17430CON(AP)	Not Assigned
APPLICANT:	TITLE:METHODS OF SCREENING AND USING
Baciu et al	INHIBITORS OF ANGIOGENESIS
FILING DATE:	GROUP:
Submitted herewith	Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	6,274,703	8/14/2001	Goldberg			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
		,	- · · · · · · · · · · · · · · · · · · ·			

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

AB	Deryugina et al, "Functional Activation of Integrin αVβ3 in Tumor Cells Expressing Membrane-Type 1 Matrix Metalloproteinase", Int. J. Cancer: 86, 15-23 (2000)
AC	Deryugina et al, "MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αVβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells", Experimental Cell Research 263, 209-223(2001)
AD	Deryugina et al, "Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma ce4lls on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase.", J. Biol. Chem. 22 March 2002, Vol. 277, No. 12, pages 9749-9756
AE	Ratnikov et al, "An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase." J. Biol. Chem. 1 March 2002, Vol. 277, No. 9, pages 7377-7385

EXAMINER_

DATE CONSIDERED _

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.